Citius Pharmaceuticals, Inc.
CTXR · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $9 | $12 | $15 | $18 |
| G&A Expenses | $19 | $18 | $22 | $16 |
| SG&A Expenses | $19 | $18 | $22 | $16 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $11 | $12 | $0 | $0 |
| Operating Expenses | $38 | $42 | $37 | $33 |
| Operating Income | -$39 | -$42 | -$37 | -$33 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | $3 | $5 | $0 |
| Pre-Tax Income | -$39 | -$39 | -$32 | -$33 |
| Tax Expense | $1 | $1 | $1 | $1 |
| Net Income | -$37 | -$39 | -$33 | -$34 |
| % Margin | – | – | – | – |
| EPS | -3.38 | -5.97 | -5.57 | -5.76 |
| % Growth | 43.4% | -7.2% | 3.3% | – |
| EPS Diluted | -3.38 | -5.97 | -5.57 | -5.76 |
| Weighted Avg Shares Out | 11 | 12 | 10 | 10 |
| Weighted Avg Shares Out Dil | 11 | 12 | 10 | 10 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $0 |
| Interest Expense | -$0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$38 | -$39 | -$32 | -$33 |
| % Margin | – | – | – | – |